Topoisomerase I and II inhibitors

A patent review

Arshdeep Singh, Navdeep Kaur, Gurpreet Singh, Pooja Sharma, P. M.S. Bedi, Sahil Sharma, Kunal Nepali

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Background: Topoisomerases are a set of nuclear enzymes that play a vital role in handling of topological consequences of DNA during various genetic activities necessary for vitality of cell. Inhibition of these enzymes consequently leads to the blockage of ligation step of the cell cycle which generates single and double strand breakage in DNA strand. Introduction of these breaks subsequently leads to programmed cell death (Apoptosis). Objective: In the past several years, topoisomerases have become one of the most expedient and strategic molecular targets for anticancer drugs and numerous patents have been filed and published on topoisomerase inhibitors. This review compiles the patent literature up to 2016 embracing topo I and II inhibitors as well as dual inhibitors which are structurally adjacent to camptothecin (CPT), natural products such as lamellarins and synthetic trisubstituted pyridines. The present assemblage can be extremely advantageous for the medicinal chemists who are in crave for the development of potential anticancer agents targeting topoisomerases. Conclusion: Recent patents indicated that some of the nitrogen containing heteroaromatic compounds have immense potential to inhibit topoisomerase enzyme. In particular, fused N-Heterocycles can be anticipated for their promising therapeutic potential alone or in combination with other anticancer agents. Naphthyridinone and indenoisoquinoline derivatives, described in the preceding sections of this review, are endowed with significant potency against topoisomerase I which clearly indicates the need of preclinical and clinical studies to place them in forefront as potential future drug candidates.

Original languageEnglish
Pages (from-to)401-423
Number of pages23
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume11
Issue number4
DOIs
Publication statusPublished - Nov 1 2016
Externally publishedYes

Fingerprint

Topoisomerase I Inhibitors
Topoisomerase II Inhibitors
Patents
Antineoplastic Agents
Enzymes
Topoisomerase Inhibitors
Pyridines
Literature
Camptothecin
Type I DNA Topoisomerase
DNA
Biological Products
Pharmaceutical Preparations
Ligation
Cell Cycle
Cell Death
Nitrogen
Apoptosis
Therapeutics

Keywords

  • Anticancer
  • Camptothecin
  • DNA
  • Enzyme
  • Inhibitors
  • Topoisomerase

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Cancer Research
  • Pharmacology (medical)

Cite this

Topoisomerase I and II inhibitors : A patent review. / Singh, Arshdeep; Kaur, Navdeep; Singh, Gurpreet; Sharma, Pooja; Bedi, P. M.S.; Sharma, Sahil; Nepali, Kunal.

In: Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, No. 4, 01.11.2016, p. 401-423.

Research output: Contribution to journalReview article

Singh, Arshdeep ; Kaur, Navdeep ; Singh, Gurpreet ; Sharma, Pooja ; Bedi, P. M.S. ; Sharma, Sahil ; Nepali, Kunal. / Topoisomerase I and II inhibitors : A patent review. In: Recent Patents on Anti-Cancer Drug Discovery. 2016 ; Vol. 11, No. 4. pp. 401-423.
@article{0d64459f1bbf4ce28a54b9531dbdf7c6,
title = "Topoisomerase I and II inhibitors: A patent review",
abstract = "Background: Topoisomerases are a set of nuclear enzymes that play a vital role in handling of topological consequences of DNA during various genetic activities necessary for vitality of cell. Inhibition of these enzymes consequently leads to the blockage of ligation step of the cell cycle which generates single and double strand breakage in DNA strand. Introduction of these breaks subsequently leads to programmed cell death (Apoptosis). Objective: In the past several years, topoisomerases have become one of the most expedient and strategic molecular targets for anticancer drugs and numerous patents have been filed and published on topoisomerase inhibitors. This review compiles the patent literature up to 2016 embracing topo I and II inhibitors as well as dual inhibitors which are structurally adjacent to camptothecin (CPT), natural products such as lamellarins and synthetic trisubstituted pyridines. The present assemblage can be extremely advantageous for the medicinal chemists who are in crave for the development of potential anticancer agents targeting topoisomerases. Conclusion: Recent patents indicated that some of the nitrogen containing heteroaromatic compounds have immense potential to inhibit topoisomerase enzyme. In particular, fused N-Heterocycles can be anticipated for their promising therapeutic potential alone or in combination with other anticancer agents. Naphthyridinone and indenoisoquinoline derivatives, described in the preceding sections of this review, are endowed with significant potency against topoisomerase I which clearly indicates the need of preclinical and clinical studies to place them in forefront as potential future drug candidates.",
keywords = "Anticancer, Camptothecin, DNA, Enzyme, Inhibitors, Topoisomerase",
author = "Arshdeep Singh and Navdeep Kaur and Gurpreet Singh and Pooja Sharma and Bedi, {P. M.S.} and Sahil Sharma and Kunal Nepali",
year = "2016",
month = "11",
day = "1",
doi = "10.2174/0929866523666160720095940",
language = "English",
volume = "11",
pages = "401--423",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Topoisomerase I and II inhibitors

T2 - A patent review

AU - Singh, Arshdeep

AU - Kaur, Navdeep

AU - Singh, Gurpreet

AU - Sharma, Pooja

AU - Bedi, P. M.S.

AU - Sharma, Sahil

AU - Nepali, Kunal

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: Topoisomerases are a set of nuclear enzymes that play a vital role in handling of topological consequences of DNA during various genetic activities necessary for vitality of cell. Inhibition of these enzymes consequently leads to the blockage of ligation step of the cell cycle which generates single and double strand breakage in DNA strand. Introduction of these breaks subsequently leads to programmed cell death (Apoptosis). Objective: In the past several years, topoisomerases have become one of the most expedient and strategic molecular targets for anticancer drugs and numerous patents have been filed and published on topoisomerase inhibitors. This review compiles the patent literature up to 2016 embracing topo I and II inhibitors as well as dual inhibitors which are structurally adjacent to camptothecin (CPT), natural products such as lamellarins and synthetic trisubstituted pyridines. The present assemblage can be extremely advantageous for the medicinal chemists who are in crave for the development of potential anticancer agents targeting topoisomerases. Conclusion: Recent patents indicated that some of the nitrogen containing heteroaromatic compounds have immense potential to inhibit topoisomerase enzyme. In particular, fused N-Heterocycles can be anticipated for their promising therapeutic potential alone or in combination with other anticancer agents. Naphthyridinone and indenoisoquinoline derivatives, described in the preceding sections of this review, are endowed with significant potency against topoisomerase I which clearly indicates the need of preclinical and clinical studies to place them in forefront as potential future drug candidates.

AB - Background: Topoisomerases are a set of nuclear enzymes that play a vital role in handling of topological consequences of DNA during various genetic activities necessary for vitality of cell. Inhibition of these enzymes consequently leads to the blockage of ligation step of the cell cycle which generates single and double strand breakage in DNA strand. Introduction of these breaks subsequently leads to programmed cell death (Apoptosis). Objective: In the past several years, topoisomerases have become one of the most expedient and strategic molecular targets for anticancer drugs and numerous patents have been filed and published on topoisomerase inhibitors. This review compiles the patent literature up to 2016 embracing topo I and II inhibitors as well as dual inhibitors which are structurally adjacent to camptothecin (CPT), natural products such as lamellarins and synthetic trisubstituted pyridines. The present assemblage can be extremely advantageous for the medicinal chemists who are in crave for the development of potential anticancer agents targeting topoisomerases. Conclusion: Recent patents indicated that some of the nitrogen containing heteroaromatic compounds have immense potential to inhibit topoisomerase enzyme. In particular, fused N-Heterocycles can be anticipated for their promising therapeutic potential alone or in combination with other anticancer agents. Naphthyridinone and indenoisoquinoline derivatives, described in the preceding sections of this review, are endowed with significant potency against topoisomerase I which clearly indicates the need of preclinical and clinical studies to place them in forefront as potential future drug candidates.

KW - Anticancer

KW - Camptothecin

KW - DNA

KW - Enzyme

KW - Inhibitors

KW - Topoisomerase

UR - http://www.scopus.com/inward/record.url?scp=85004090214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004090214&partnerID=8YFLogxK

U2 - 10.2174/0929866523666160720095940

DO - 10.2174/0929866523666160720095940

M3 - Review article

VL - 11

SP - 401

EP - 423

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

IS - 4

ER -